Long before the tram. Nothing but strollers and the guys pushing the chairs along the boardwalk. Barkers selling all kinds of gadgets, gathering crowds of vacationers along the strand. Great times at the Jersey Shore and no Casinos.
I think it is a question of volumes at this point. STM has shown a smaller engine and I'm quite sure Sony is on track or has already duplicated it. After all, it was their intention to make the Gen2 smaller and brighter and more efficient. I do believe they are a good way down the line to making that happen, and soon. I have seen amazing production happen when the cash is on the table and they are all looking at the bundle of cash out there right now. As our politicians her in Pa. say, "Money talks and BS walks".
Don't think I'll fight the traffic this weekend so you won't hear me screaming and dancing at 9th Street beach. That would be an airshow to top Atlantic City's by a lot. Just as good as the Blue Angels for me as I am loaded and waiting.
That lenova product is one sweet looking machine. I am almost 100% sure they are using our tech, so I doubt they are using DLP, however you never know with Tokman. Can't find anything saying Focus Free or always in focus to help. I can find DLP without much effort. The late move up didn't come from Sony and the lack of acknowledgment irritates me. A battery charge lasting 18 hours is great and that is what picop needs. Had hoped to see Sony take the lead as we know they are using MVIS. Interesting times ahead.
My thoughts also. We need at least 50 lumen and smaller foot print. Sony has had 18 months or so to work with it. I'm not so sure we won't see that soon as the shots have been fired loud and clear, and cell phones are the big ticket.
I think that I knew it last year at CES when our guy was told it is Sony by the Celluon folks. No image by Picop seen anywhere. They are doing all the work now and will claim it is theirs. Hoping a little acknowledgment makes its way to MVIS.
I've been saying this for a long, long time, Partnerships and data. That is the main source of a better pps and better investors. RS and offerings without great data will make the road a lot rougher for small bio's. The AZN deal was great and now we need the quality investors that Dr. Kim was aiming for with the RS, I don't see them yet. Institutional investment has increased, but not nearly enough. P2 was not, not what the street was looking for even though it has paved the way for P3 and it will be a year and a half lag, go figure. The street isn't buying Dr. Kim's road shows any more. I am sure we are sitting on good news that will help propel the pps soon, but this company does not promote itself well at all. We sell off big when the market hic cups and we struggle between PR's. We should be higher just on our pipeline and partners we have. It's hard to convince those "go it alone" retail guys that we just have to have big pharma and we need more of them. ONly way to get the best of the pipeline into trials without issuing shares to infinity.
Didn't mean to show my hand, those numbers were in response to an idiot post. Never intended to hold this much as I think it won't take a heii of a lot of shares to make us all happy. I most likely won't ever reveal numbers again.
No vote, we need institutional investors and not totally dominated by retail. It does make a big difference.